Literature DB >> 26984878

Vertebral body fracture after TLIF: a new complication.

Philip A Saville1, Jason B Anari1, Harvey E Smith2,3, Vincent Arlet4,5.   

Abstract

BACKGROUND: The transforaminal posterior approach (TLIF) procedure was first described in 1982. Current literature indicates its equality in outcomes for fusion constructs as other anterior-posterior procedures. As a procedure becomes more popular and is more frequently performed the types and number of complications that occur increase. We report on a two case series that underwent TLIF. Both patients had satisfactory postoperative imaging, but presented later with coronal plane vertebral body fractures in the caudal vertebral body of the TLIF construct. We believe the complication may be related to: (a) unrecognized fracture of the endplate during cage impaction; (b) overloading the endplates by maximizing the lordosis achieved by using the reverse jackknife position on a Jackson table; (c) underlying mineral bone disease in patients. As the TLIF procedure increases in popularity, caution should be exercised to avoid the same potential complications.
PURPOSE: To describe a potential complication with the TLIF procedure. STUDY
DESIGN: Case report. PATIENT SAMPLE: 2. OUTCOME MEASURE: Revision surgery.
METHODS: Case series.
RESULTS: Caudal vertebral body fracture is a potential complication after TLIF.
CONCLUSION: TLIF procedures can result in an unstable vertebral body fracture potentially necessitating revision decompression & stabilization. We recommend extra caution in patients with mineral bone disease, as technical errors can be magnified.

Entities:  

Keywords:  Lumbar fusion; Revision surgery; TLIF; Vertebral fracture

Mesh:

Year:  2016        PMID: 26984878     DOI: 10.1007/s00586-016-4517-1

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  7 in total

1.  Anterior/posterior lumbar fusion versus transforaminal lumbar interbody fusion: analysis of complications and predictive factors.

Authors:  H T Hee; F P Castro; M E Majd; R T Holt; L Myers
Journal:  J Spinal Disord       Date:  2001-12

2.  Transforaminal lumbar interbody fusion: a safe technique with satisfactory three to five year results.

Authors:  Lars Hackenberg; Henry Halm; Viola Bullmann; Volker Vieth; Marc Schneider; Ulf Liljenqvist
Journal:  Eur Spine J       Date:  2005-01-26       Impact factor: 3.134

3.  Comparison of posterior and transforaminal approaches to lumbar interbody fusion.

Authors:  S C Humphreys; S D Hodges; A G Patwardhan; J C Eck; R B Murphy; L A Covington
Journal:  Spine (Phila Pa 1976)       Date:  2001-03-01       Impact factor: 3.468

4.  Perioperative complications in transforaminal lumbar interbody fusion versus anterior-posterior reconstruction for lumbar disc degeneration and instability.

Authors:  Alan T Villavicencio; Sigita Burneikiene; Ketan R Bulsara; Jeffrey J Thramann
Journal:  J Spinal Disord Tech       Date:  2006-04

5.  Transforaminal lumbar interbody fusion: clinical and radiographic results and complications in 100 consecutive patients.

Authors:  Benjamin K Potter; Brett A Freedman; Eric G Verwiebe; Jordan M Hall; David W Polly; Timothy R Kuklo
Journal:  J Spinal Disord Tech       Date:  2005-08

6.  Transforaminal interbody fusion versus anterior-posterior interbody fusion of the lumbar spine: a financial analysis.

Authors:  T S Whitecloud ; W W Roesch; J E Ricciardi
Journal:  J Spinal Disord       Date:  2001-04

7.  Contralateral radiculopathy after transforaminal lumbar interbody fusion.

Authors:  Travis Hunt; Francis H Shen; Christopher I Shaffrey; Vincent Arlet
Journal:  Eur Spine J       Date:  2007-05-09       Impact factor: 3.134

  7 in total
  1 in total

1.  Complications in TLIF spondylodesis-do they influence the outcome for patients? A prospective two-center study.

Authors:  Philipp Poppenborg; Ulf Liljenqvist; Georg Gosheger; Albert Schulze Boevingloh; Lukas Lampe; Sebastian Schmeil; Tobias L Schulte; Tobias Lange
Journal:  Eur Spine J       Date:  2020-12-22       Impact factor: 3.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.